1. Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus
- Author
-
Nicholas S. Britt, Misty M. Miller, Renata O. Smith, Elizabeth M Sherman, Emily Huesgen, Kathleen Nowak, Michelle M. Lewis, and Melissa E Badowski
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Transgender people ,medicine.medical_treatment ,030106 microbiology ,Human immunodeficiency virus (HIV) ,HIV Infections ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Transgender Persons ,Article ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Transgender ,Humans ,Medicine ,Drug Interactions ,Pharmacology (medical) ,Intensive care medicine ,business.industry ,Antiretroviral therapy ,Female ,Hormone therapy ,business - Abstract
Pharmacotherapy considerations are often a concern for transgender individuals who are living with human immunodeficiency virus (HIV) due to concerns for drug-drug interactions between their hormone and antiretroviral therapies. Many of the first-line therapies offered to patients for the management of HIV have reduced concerns for safety, resistance, and drug-drug interactions. In this review, we highlight common medications and important considerations for caring for transgender people living with HIV.
- Published
- 2021
- Full Text
- View/download PDF